Percheron Therapeutics Limited
PERCF
$0.0025
-$0.0165-86.84%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 47.17% | 41.17% | 35.44% | 107.87% | 1,082.28% |
| Total Other Revenue | -253.04% | -256.97% | -140.00% | -68.18% | -68.39% |
| Total Revenue | -28.89% | 3.66% | 47.01% | 34.94% | 24.98% |
| Cost of Revenue | 103.47% | 98.65% | 83.78% | 53.33% | 30.21% |
| Gross Profit | -31.75% | 1.80% | 46.38% | 34.59% | 24.87% |
| SG&A Expenses | 47.28% | 39.24% | 28.92% | 14.34% | 0.63% |
| Depreciation & Amortization | -28.68% | -23.22% | -18.75% | -10.47% | -1.10% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.56% | 19.44% | 8.64% | 16.64% | 28.43% |
| Operating Income | -42.70% | -22.74% | -2.01% | -12.84% | -29.31% |
| Income Before Tax | -43.45% | -23.14% | -2.07% | -13.00% | -29.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.45% | -23.14% | -2.07% | -13.00% | -29.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.45% | -23.14% | -2.07% | -13.00% | -29.65% |
| EBIT | -42.70% | -22.74% | -2.01% | -12.84% | -29.31% |
| EBITDA | -43.02% | -22.68% | -1.67% | -12.44% | -28.81% |
| EPS Basic | -3.88% | 9.26% | 22.81% | 4.04% | -24.10% |
| Normalized Basic EPS | -1.54% | 11.76% | 25.00% | 4.84% | -25.00% |
| EPS Diluted | -1.90% | 9.17% | 21.05% | 2.02% | -26.51% |
| Normalized Diluted EPS | -1.54% | 11.76% | 25.00% | 4.84% | -25.00% |
| Average Basic Shares Outstanding | 41.43% | 36.69% | 31.74% | 17.76% | 3.83% |
| Average Diluted Shares Outstanding | 41.43% | 36.69% | 31.74% | 17.76% | 3.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |